滚动市盈率

Search documents
洲际油气收盘下跌1.64%,滚动市盈率22.98倍,总市值99.58亿元
Sou Hu Cai Jing· 2025-07-28 10:53
Group 1 - The core viewpoint of the news is that Intercontinental Oil and Gas has a current stock price of 2.4 yuan, with a decline of 1.64%, and a rolling PE ratio of 22.98 times, indicating a higher valuation compared to the industry average [1] - The total market capitalization of Intercontinental Oil and Gas is 99.58 billion yuan, ranking 12th in the oil industry based on PE ratio, which has an average of 12.99 times and a median of 30.50 times [1][2] - As of May 9, 2025, the number of shareholders in Intercontinental Oil and Gas is 99,607, a decrease of 5,007 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business of Intercontinental Oil and Gas includes oil exploration and development, investment in petrochemical projects, and related engineering technical development, consulting, and services [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 547 million yuan, a year-on-year decrease of 14.14%, and a net profit of 42.56 million yuan, down 56.06% year-on-year, with a gross profit margin of 57.30% [1]
开立医疗收盘下跌1.05%,滚动市盈率276.08倍,总市值138.81亿元
Sou Hu Cai Jing· 2025-07-28 09:48
Core Viewpoint - The company, Kaili Medical, is experiencing a decline in stock price and profitability, with a high PE ratio compared to industry averages, indicating potential overvaluation in the medical device sector [1][2]. Company Overview - Kaili Medical specializes in the research, development, production, and sales of medical diagnostic and treatment equipment, including ultrasound diagnostic devices, endoscopes, minimally invasive surgical products, and cardiovascular intervention products [1]. - The company has over 20 years of experience in the ultrasound industry and is recognized as a high-tech enterprise, having developed core technologies for color Doppler ultrasound machines and probes [1]. - Kaili Medical holds the second-largest market share among domestic manufacturers in China and ranks tenth globally in the ultrasound market, showcasing strong brand influence and competitiveness [1]. Financial Performance - For the first quarter of 2025, Kaili Medical reported revenue of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit of 8.07 million yuan, down 91.94% compared to the previous year [1]. - The company's gross profit margin stands at 63.19% [1]. Market Position - As of July 28, 2023, Kaili Medical's stock closed at 32.08 yuan, with a rolling PE ratio of 276.08, significantly higher than the industry average of 55.28 and the median of 38.06 [1][2]. - The total market capitalization of Kaili Medical is 13.881 billion yuan [1][2]. - There are 32 institutional investors holding shares in Kaili Medical, with a total holding of 24.7034 million shares valued at 734 million yuan [1].
理邦仪器收盘上涨1.71%,滚动市盈率40.22倍,总市值75.88亿元
Sou Hu Cai Jing· 2025-07-28 09:13
Core Insights - The company, Lifesense Medical, closed at 13.09 yuan on July 28, with a 1.71% increase, and a rolling PE ratio of 40.22, marking a new low in 104 days, with a total market capitalization of 7.588 billion yuan [1][2] - The average PE ratio in the medical device industry is 55.28, with a median of 38.06, placing Lifesense Medical at the 79th position in the industry ranking [1][2] - As of the first quarter of 2025, four institutions held shares in Lifesense Medical, with a total of 55,200 shares valued at 0.01 million yuan [1] Company Overview - Lifesense Medical specializes in the research, development, production, sales, and service of medical electronic devices and in vitro diagnostic products [1] - Key products include critical care monitoring solutions, bedside monitoring solutions, intelligent vital signs management solutions, various ECG systems, ultrasound diagnostic systems, perinatal monitoring solutions, gynecological diagnostic solutions, blood gas analyzers, and molecular diagnostic products [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit was 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [2] - The sales gross margin stood at 58.34% [2]
东富龙收盘下跌1.26%,滚动市盈率72.05倍,总市值107.75亿元
Sou Hu Cai Jing· 2025-07-28 09:13
Group 1 - The core business of the company is to provide pharmaceutical companies worldwide with pharmaceutical processes, core equipment, and overall system engineering solutions [1] - The company's main products include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] - As of the first quarter of 2025, the company reported revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, and a net profit of 20.1326 million yuan, a year-on-year decrease of 68.87% [1] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 72.05, significantly higher than the industry average of 55.28 and the industry median of 38.06 [2] - The total market capitalization of the company is 10.775 billion yuan [2] - As of the first quarter of 2025, there is only one institutional holder of the company, with a total holding of 2.1845 million shares valued at 2.9 million yuan [1]
亚钾国际收盘上涨4.68%,滚动市盈率24.25倍,总市值304.01亿元
Sou Hu Cai Jing· 2025-07-28 08:32
Group 1 - The core viewpoint of the news is that Yara International's stock price has increased by 4.68% to 32.9 yuan, with a rolling PE ratio reaching a new low of 24.25 times over the past 694 days, and a total market capitalization of 30.401 billion yuan [1] - The average PE ratio for the fertilizer industry is 26.09 times, with a median of 23.06 times, placing Yara International at the 17th position within the industry [1] - On July 28, Yara International experienced a net outflow of 10.151 million yuan in main funds, continuing a trend of outflows over the past five days, totaling 142.976 million yuan [1] Group 2 - Yara International's main business includes potassium salt mining, potassium fertilizer production, and sales, with key products being potassium chloride, brine, and others [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 1.213 billion yuan, a year-on-year increase of 91.47%, and a net profit of 384 million yuan, a year-on-year increase of 373.53%, with a sales gross margin of 54.12% [1]
超研股份收盘上涨1.95%,滚动市盈率73.53倍,总市值116.38亿元
Sou Hu Cai Jing· 2025-07-25 10:14
Company Overview - Chao Yan Co., Ltd. closed at 27.17 yuan, up 1.95%, with a rolling PE ratio of 73.53, marking a new low in 14 days, and a total market value of 11.638 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.41 and a median of 37.94, placing Chao Yan at the 96th position in the industry ranking [1] - As of the first quarter of 2025, 118 institutions held shares in Chao Yan, with a total holding of 71,100 shares valued at 0.02 billion yuan [1] Business Operations - Chao Yan specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [1] - The main products include industrial ultrasound, medical ultrasound, X-ray, and related accessories [1] - The company has established a strong market presence and stable customer base, with its industrial ultrasound non-destructive testing products recognized as a Guangdong Province brand [1] - In 2022, the company received a second-class National Defense Technology Invention Award from the Ministry of Industry and Information Technology for its project on "New Technology for High-Precision Non-Destructive Testing of Complex Large Components and Its Major Applications" [1] Financial Performance - In the first quarter of 2025, Chao Yan reported operating revenue of 98.4324 million yuan, a year-on-year increase of 28.69% [1] - The net profit for the same period was 39.3220 million yuan, reflecting a year-on-year growth of 47.70% [1] - The sales gross margin stood at 73.83% [1]
英科医疗收盘上涨3.40%,滚动市盈率12.99倍,总市值205.18亿元
Sou Hu Cai Jing· 2025-07-25 09:45
Core Viewpoint - The company Inco Medical has shown a significant increase in stock price and profitability, but it is experiencing a net outflow of funds, indicating potential investor concerns despite strong financial performance [1][2]. Company Summary - Inco Medical's stock closed at 31.34 yuan, up 3.40%, with a rolling PE ratio of 12.99 times and a total market capitalization of 20.518 billion yuan [1]. - The company specializes in the research, production, and sales of high-performance personal protective products, including disposable nitrile gloves, PVC gloves, isolation gowns, masks, and various medical equipment [1]. - For Q1 2025, Inco Medical reported revenue of 2.494 billion yuan, a year-on-year increase of 13.20%, and a net profit of 353 million yuan, reflecting a year-on-year growth of 48.08% with a gross profit margin of 24.16% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.41 times, with a median of 37.94 times, positioning Inco Medical at the 32nd rank within the industry [1][2]. - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2].
开立医疗收盘上涨1.82%,滚动市盈率279.00倍,总市值140.29亿元
Sou Hu Cai Jing· 2025-07-25 09:45
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kaili Medical, indicating a significant decline in revenue and profit in the latest quarter [1][2] - As of July 25, Kaili Medical's stock closed at 32.42 yuan, with a PE ratio of 279.00, marking a new low in 32 days, and a total market capitalization of 14.029 billion yuan [1] - The average PE ratio for the medical device industry is 55.41, with a median of 37.94, positioning Kaili Medical at 118th in the industry ranking [1][2] Group 2 - In the first quarter of 2025, the company reported an operating income of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit of 8.0746 million yuan, down 91.94% [2] - The company's gross profit margin stands at 63.19%, indicating a relatively high profitability despite the decline in revenue and net profit [2] - Kaili Medical specializes in the research, development, production, and sales of medical diagnostic and treatment equipment, with a strong presence in the ultrasound industry and a market share ranking second among domestic manufacturers and tenth globally [1]
中粮资本收盘下跌1.56%,滚动市盈率44.03倍,总市值291.47亿元
Sou Hu Cai Jing· 2025-07-25 08:54
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of COFCO Capital, noting a decline in stock price and profitability [1][2] - As of July 25, COFCO Capital's stock closed at 12.65 yuan, down 1.56%, with a rolling PE ratio of 44.03 times and a total market capitalization of 29.147 billion yuan [1] - The average PE ratio for the diversified financial industry is 42.44 times, with a median of 29.55 times, placing COFCO Capital at the 14th position within the industry [1][2] Group 2 - As of July 10, 2025, COFCO Capital had 136,000 shareholders, an increase of 10,000 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business focuses on the research and design of financial services, primarily offering trust investment products and insurance products [1] - In the latest quarterly report for Q1 2025, COFCO Capital reported operating revenue of 2.35 billion yuan, a year-on-year decrease of 8.74%, and a net profit of 392 million yuan, down 58.32%, with a gross profit margin of 52.97% [1]
弘业期货收盘下跌4.13%,滚动市盈率285.30倍,总市值126.38亿元
Jin Rong Jie· 2025-07-25 08:46
Group 1 - The core viewpoint of the article highlights the financial performance and market position of Hongye Futures, indicating a significant drop in stock price and a high PE ratio compared to industry averages [1][2] - As of July 25, Hongye Futures closed at 12.54 yuan, down 4.13%, with a rolling PE ratio of 285.30 times and a total market capitalization of 12.638 billion yuan [1] - The average PE ratio for the multi-financial industry is 42.44 times, with a median of 29.55 times, placing Hongye Futures at the 20th position in the industry ranking [1][2] Group 2 - On July 25, Hongye Futures experienced a net outflow of main funds amounting to 69.1751 million yuan, with a total outflow of 103.8488 million yuan over the past five days [1] - The main business activities of Hongye Futures include commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, and fund sales [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 643 million yuan, a year-on-year increase of 259.09%, and a net profit of 1.2032 million yuan, up 109.07% year-on-year [1]